119-hres803

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 803 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
H. RES. 803

 Urging the Director of the Food and Drug Administration to reevaluate 
 the safety of all chemical abortion drugs in light of recent 
 independent studies, and for other purposes.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 October 10, 2025

 Mr. Rose (for himself, Mrs. Harshbarger, Mr. Carter of Georgia, Mr. 
 LaMalfa, Mrs. Biggs of South Carolina, Mr. Moore of Alabama, Ms. 
 Hageman, and Mr. Grothman) submitted the following resolution; which 
 was referred to the Committee on Energy and Commerce

_______________________________________________________________________

 RESOLUTION

 Urging the Director of the Food and Drug Administration to reevaluate 
 the safety of all chemical abortion drugs in light of recent 
 independent studies, and for other purposes.

Whereas the Obama administration expanded access to chemical abortion drugs by 
 removing in-person administration requirements, eliminating requirements 
 for prescribers to report serious adverse effects, and removing follow-
 up care obligations;
Whereas the Biden administration further expanded access to chemical abortion 
 drugs by removing in-person dispensing requirements, permitting these 
 drugs to be distributed by mail;
Whereas the expansion of access to chemical abortion drugs has raised serious 
 concerns regarding potential violations of Federal law, increased risks 
 of coercion and domestic abuse, and even intentional misuse resulting in 
 harm or death;
Whereas chemical abortions now account for more than half of all abortions 
 performed in the United States;
Whereas many providers prescribing chemical abortion drugs receive taxpayer 
 funding, raising ethical and legal concerns regarding the use of public 
 funds;
Whereas, on September 30, 2025, the Food and Drug Administration approved a new 
 generic version of mifepristone, further expanding the availability of 
 chemical abortion drugs;
Whereas this approval will likely contribute to a significant increase in the 
 number of unborn children lost to abortion, and poses a risk of 
 potential physical and emotional harm to women and girls, while 
 undermining pro-life laws enacted by numerous States; and
Whereas independent research suggests that chemical abortions carry a rate of 
 serious complications that is 22 times higher than what is currently 
 reported by the Food and Drug Administration and drug manufacturers: 
 Now, therefore, be it
 Resolved, That the House of Representatives urges the Director of 
the Food and Drug Administration--

    (1) to reevaluate the safety of all chemical abortion drugs 
 in light of recent independent studies; and

    (2) to publicly release a full safety review of such drugs 
 that includes real-world outcomes and complications.
 <all>